Synlogic to participate in chardan's genetic medicines conference

Cambridge, mass., sept. 21, 2023 (globe newswire) -- synlogic, inc. (nasdaq: sybx), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced its management team will participate in chardan's 7th annual genetic medicines conference, being held in new york, october 2-3, 2023. in addition to one-on-one meetings with investors, synlogic ceo dr. aoife brennan will participate in a fireside chat on monday, october 2 at 4:30 p.m. eastern time.
SYBX Ratings Summary
SYBX Quant Ranking